BACKGROUND The addition of rituximab to CHOP (R-CHOP; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improves outcome in patients with diffuse large B-cell lymphoma (DLBCL). We evaluated the risk of central nervous system (CNS) relapse in the R-CHOP in a population-based cohort of patients with DLBCL. METHODS Patients with DLBCL diagnosed from 1 September 1999 ...

Central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) is a rare complication, but has a poor prognosis with unknown pathophysiology. Recent trials of CNS prophylaxis have shown to be ineffective, despite patient's selection using several known clinical risk factors. In this study, the authors evaluated the value of pretreatment [F]2-Fluoro-2-deoxyglucose positron emissio...

BACKGROUND Primary testicular diffuse large B-cell lymphoma (DLBCL) is a rare but aggressive extranodal lymphoma, and its relapse in the central nervous system (CNS) is a major concern during treatment. Despite this, the role of intrathecal prophylaxis in primary testicular DLBCL remains controversial. METHODS We retrospectively reviewed the medical records of 14 patients with primary testicu...

The Children's Cancer Group (CCG) 1952 clinical trial for children with standard-risk acute lymphoblastic leukemia (SR-ALL) compared intrathecal (IT) methotrexate (MTX) with IT triples (ITT) (MTX, cytarabine, and hydrocortisone sodium succinate [HSS]) as presymptomatic central nervous system (CNS) treatment. Following remission induction, 1018 patients were randomized to receive IT MTX and 1009...

Introduction: We analyzed the incidence, risk factors of central nervous system (CNS) relapse and outcome CNS involvement in patients with peripheral T-cell lymphomas (PTCL) prospectively observed Czech Lymphoma Study Group Registry (NCT03199066). Methods: Out 1040 we identified 29 (2.79%) involvement: 13 (1.25%) had disease at initial diagnosis 16 (1.54%) relapse. Median age was 61 years 54.5 ...

Hypopituitarism in leukemia is very rare. In addition, central nervous system (cns) relapse and leukemic retinopathy in childhood acute lymphoblastic leukemia (all) have declined with the use of modern systemic chemotherapy that includes cns prophylaxis. Here, we report the case of a 4-year-old girl who received chemotherapy and intrathecal therapy without cns radiation after a diagnosis of B-p...

Abnormalities of the thyroid gland are among the most frequent endocrine complications observed in childhood cancer survivors. We report an 11 years old girl who developed central hypothyroidism and ACTH deficiency during the chemotherapy for CNS relapse of acute lymphoblastic leukemia before receiving radiotherapy. Keywords: Thyroid gland, hypothyroidism, chemotherapy, acute lymphoblastic leu...

Central nervous system (CNS) relapse is not a rare presentation in acute myeloid leukemia (AML) as its incidence ranges between 2% and 9%. It manifests with meningeal leukemia, cranial nerve palsies or cerebral mesenchymal myeloid sarcoma. We herein report the case of a 69 year-old female that presented a pseudo-Guillain-Barré syndrome masking an AML CNS relapse. Her symptoms completely resolve...

Acute lymphoblastic leukemia (ALL) is the most common cancer in children. While survival rates for ALL have improved, central nervous system (CNS) relapse remains a significant cause of treatment failure and treatment-related morbidity. Accordingly, there is a need to identify more efficacious and less toxic CNS-directed leukemia therapies. Extensive research has demonstrated a critical role of...

To the Editor: We read with interest the article by Chow and Feusner [1] as well as the letter by Kaspers et al. [2] and response from Feusner and Chow [3] regarding isolated central nervous system (CNS) relapse of acute promyelocytic leukemia (APL) in children. They found a total incidence of CNS relapse of 6/431 (1.39%), and in good risk patients an incidence of truly isolated CNS relapse of ...